Paradoxical oncogenesis: are all BRAF inhibitors equal?
Article first published online: 19 JUL 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Pigment Cell & Melanoma Research
Volume 26, Issue 5, pages 611–615, September 2013
How to Cite
Menzies, A. M., Kefford, R. F. and Long, G. V. (2013), Paradoxical oncogenesis: are all BRAF inhibitors equal?. Pigment Cell & Melanoma Research, 26: 611–615. doi: 10.1111/pcmr.12132
- Issue published online: 23 AUG 2013
- Article first published online: 19 JUL 2013
- Accepted manuscript online: 24 JUN 2013 07:21AM EST
- Manuscript Accepted: 19 JUN 2013
- Manuscript Received: 23 MAY 2013
- BRAF inhibitor;
- squamous cell carcinoma;
- secondary malignancy
Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.